John Harry Cross III - Mar 7, 2025 Form 4 Insider Report for Senti Biosciences, Inc. (SNTI)

Role
Chief Financial Officer
Signature
/s/ Robert Cutler, attorney-in-fact
Stock symbol
SNTI
Transactions as of
Mar 7, 2025
Transactions value $
$0
Form type
4
Date filed
3/11/2025, 04:14 PM
Previous filing
Mar 11, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNTI Stock Option (Right to Buy) Award $0 +174K $0.00 174K Mar 7, 2025 Common Stock 174K $3.52 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this option vest on March 3, 2026 and the remainder vest in 36 substantially equal monthly installments thereafter, subject to the reporting person's continued service through the applicable vesting date.